Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R61 NS113258)
Received: 19 January 2022
Accepted: 6 July 2022
First Online: 27 July 2022
: D.M.R. has an equity stake in Clarified Precision Medicine, LLC. D.M.R. has received research support from Novo Nordisk, consulting honoraria from Pharmazaam, LLC, and Interpares Biomedicine. D.M.R. owns intellectual property related to the detection of type-2 diabetes, chronic liver disease and liver cancer. The remaining authors declare no competing interests.